These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11398649)

  • 1. [New thrombolytic agents. Thrombin and factor Xa inhibitors].
    Heinzl S
    Med Monatsschr Pharm; 2001 May; 24(5):142-6. PubMed ID: 11398649
    [No Abstract]   [Full Text] [Related]  

  • 2. Factor Xa inhibitors: today and beyond.
    Walenga JM; Jeske WP; Hoppensteadt D; Fareed J
    Curr Opin Investig Drugs; 2003 Mar; 4(3):272-81. PubMed ID: 12735228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombin and anti-Xa agents in the control of thrombogenesis.
    Fareed J; Shaikh T; Hoppensteadt DA
    Pharmazie; 2001 Oct; 56 Suppl 1():S12-21. PubMed ID: 11686086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective and dual action orally active inhibitors of thrombin and factor Xa.
    Young RJ; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Hubbard JA; Kelly HA; Pateman AJ; Patikis A; Senger S; Shah GP; Toomey JR; Watson NS; Zhou P
    Bioorg Med Chem Lett; 2007 May; 17(10):2927-30. PubMed ID: 17420122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model.
    Suleymanov OD; Szalony JA; Salyers AK; LaChance RM; Parlow JJ; South MS; Wood RS; Nicholson NS
    J Pharmacol Exp Ther; 2003 Sep; 306(3):1115-21. PubMed ID: 12829728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [From heparin to synthetic antithrombotic oligosaccharides].
    Petitou M
    Bull Acad Natl Med; 2003; 187(1):47-56; discussion 56-7. PubMed ID: 14556453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3.
    Dönnecke D; Schweinitz A; Stürzebecher A; Steinmetzer P; Schuster M; Stürzebecher U; Nicklisch S; Stürzebecher J; Steinmetzer T
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3322-9. PubMed ID: 17462889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel anticoagulants based on direct inhibition of thrombin and factor Xa.
    Gardell SJ; Sanderson PE
    Coron Artery Dis; 1998; 9(2-3):75-81. PubMed ID: 9647407
    [No Abstract]   [Full Text] [Related]  

  • 9. Will warfarin soon be passé? New approaches to stroke prevention in atrial fibrillation.
    Hammwöhner M; Goette A
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):18-27. PubMed ID: 18594479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New anticoagulants for atrial fibrillation.
    De Caterina R; Kristensen SD; Renda G
    J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):446-53. PubMed ID: 19365276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
    Andersen JC
    Semin Thromb Hemost; 2004 Dec; 30(6):609-18. PubMed ID: 15630666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
    Petitou M; Duchaussoy P; Herbert JM; Duc G; El Hajji M; Branellec JF; Donat F; Necciari J; Cariou R; Bouthier J; Garrigou E
    Semin Thromb Hemost; 2002 Aug; 28(4):393-402. PubMed ID: 12244487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leech-derived thrombin inhibitors: from structures to mechanisms to clinical applications.
    Corral-Rodríguez MA; Macedo-Ribeiro S; Pereira PJ; Fuentes-Prior P
    J Med Chem; 2010 May; 53(10):3847-61. PubMed ID: 20155915
    [No Abstract]   [Full Text] [Related]  

  • 14. Unresolved issues in the prevention and treatment of venous thromboembolism.
    Agnelli G
    Semin Thromb Hemost; 2002 Jun; 28 Suppl 2():33-40. PubMed ID: 12073178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic therapies for stroke prevention in atrial fibrillation.
    Economides Muñoz C; Singh BN
    Minerva Cardioangiol; 2004 Apr; 52(2):125-39. PubMed ID: 15194994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.
    Steffel J; Lüscher TF
    J Cardiovasc Med (Hagerstown); 2009 Aug; 10(8):616-23. PubMed ID: 19561526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for the use of antifactor Xa in the treatment and prevention of venous and arterial thromboembolic events.
    Drouet L; Bal Dit Sollier C
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():21-6. PubMed ID: 15701144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Haemostasis. A search for an ideal antithrombotics agent].
    de Moerloose P; Boehlen F
    Rev Med Suisse; 2005 Jan; 1(1):35-8. PubMed ID: 15773196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rivaroxaban: mode of action].
    Drouet L
    Ann Fr Anesth Reanim; 2008 Dec; 27 Suppl 3():S9-15. PubMed ID: 19185786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.